JBIO Jade Biosciences, Inc.
Jade Biosciences, Inc. (JBIO) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.73 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.7% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Jade Biosciences, Inc.
Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass.
Sector
Healthcare
Industry
Biotechnology